Thrombelastographic studies on factor XIII

• References

• 1 Theusinger OM, Baulig W, Asmis LM. et al. In vitro factor XIII supplementation increases clot firmness in rotation thrombelastometry (ROTEM). Thromb Haemost 2010; 104: 385-391.
• 2 McDonagh J, McDonagh RP, Delage JM. et al. Factor XIII in human plasma and platelets. J Clin Invest 1969; 48: 940-946.
• 3 Tyler HM. Fibrin crosslinking demonstrated by thrombelastography. Thromb Diath Haemorrh 1969; 22: 398-400.
• 4 Henderson KW, Nussbaum M. Mechanism of enhanced streptokinase-induced clot lysis following in-vitro factor-XIII inactivation. Br J Haematol 1969; 17: 445-453.
• 5 Calatzis A, Gödje O, Haas S. et al. Erhöhung der Gerinnselfestigkeit vor und nach herzchirurgischen Eingriffen durch Zusatz von Faktor XIII in vitro. In: Klinische Aspekte des Faktor-XIII Mangels. Diagnostik, klinische Relevanz, klinische Forschung. Karger; 1999. pp. 55-62.
• 6 Glidden PF, Malaska C, Herring SW. Thrombelasto-graph assay for measuring the mechanical strength of fibrin sealant clots. Clin Appl Thromb Hemost 2000; 6: 226-233.
• 7 Schroeder V, Chatterjee T, Kohler HP. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thrombelastography. Thromb Res 2001; 104: 467-474.
• 8 Chandler WL, Patel MA, Gravelle L. et al. Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis 2001; 12: 101-108.
• 9 Kucher N, Schroeder V, Kohler HP. Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness. Thromb Haemost 2003; 90: 434-438.
• 10 Nielsen VG, Gurley WQ, Burch TM. The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography. Anesth Analg 2004; 99: 120-123.
• 11 Wettstein P, Haeberli A, Stutz M. et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg 2004; 99: 1564-1569.
• 12 Lovejoy AE, Reynolds TC, Visich JE. et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108: 57-62.
• 13 Nielsen VG, Cohen BM, Cohen E. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coagul Fibrinolysis 2006; 17: 75-81.
• 14 Nielsen VG, Steenwyk BL, Gurley WQ. Contact activation prolongs clot lysis time in human plasma: role of thrombin-activatable fibrinolysis inhibitor and factor XIII. J Heart Lung Transplant 2006; 25: 1247-1252.
• 15 Nielsen VG, Kirklin JK, Hoogendoorn H. et al. Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics. Blood Coagul Fibrinolysis 2007; 18: 145-150.
• 16 Weber CF, Jambor C, Marquardt M. et al. Erfassung eines Faktor-XIII-Mangels mit der Thrombelastometrie. Anaesthesist 2008; 57: 487-490.
• 17 Haas T, Fries D, Velik-Salchner C. et al. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution. Anesth Analg 2008; 106: 1360-1365.
• 18 Dargaud Y, de Mazancourt P, Rugeri N. et al. An un-usual clinical presentation of factor XIII deficiency and issues relating to the monitoring of factor XIII replacement therapy. Blood Coagul Fibrinolysis 2008; 19: 447-452.
• 19 Johansson PI, Jacobsen N, Viuff D. et al. Differential clot stabilising effects of rFVIIa and rFXIII-A2 in whole blood from thrombocytopenic patients and healthy volunteers. Br J Haematol 2008; 143: 559-569.
• 20 Korte WC, Szadkowski C, Gähler A. et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 2009; 110: 239-245.
• 21 Jámbor C, Reul V, Schnider TW. et al. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood. Aneth Analg 2009; 109: 1023-1028.